Table 1.
Patients’ characteristics
| Datum | Conditioning | All Patients (N=1181) | |||
|---|---|---|---|---|---|
| Myeloablative (N=774) | Nonmyeloablative (N=407) | ||||
| Cyclosporine (N=451) | Tacrolimus (N=323) | Cyclosporine (N=280) | Tacrolimus (N=127) | ||
| Sex (Female/male, %) | 45/55 | 42/58 | 40/60 | 46/54 | 43/57 |
| Female donor to male recipient (%) | 24 | 26 | 26 | 22 | 25 |
| Patients’ age, years (median, range) | 45 (19–66) | 45 (18–67) | 56 (18–79) | 57 (20–74) | 49 (18–79) |
| Donors’ age, years (median, range) | 40 (10–74) | 38 (15–80) | 43 (18–83) | 46 (20–77) | 41 (10–83) |
| Donor type (Related/unrelated, %) | 58/42 | 49/51 | 52/48 | 53/47 | 54/46 |
| PBSC/marrow, % | 85/15 | 86/14 | 99/1 | 100/0 | 91/9 |
| Disease risk (low/high, %) | 66/34 | 72/18 | 38/62 | 45/55 | 59/41 |
| Year of transplantation (N patients) | |||||
| 2001 | 117 | 1 | 51 | -- | 169 |
| 2002 | 112 | 1 | 49 | -- | 162 |
| 2003 | 114 | 3 | 52 | 1 | 170 |
| 2004 | 84 | 21 | 38 | 9 | 152 |
| 2005 | 18 | 100 | 21 | 30 | 169 |
| 2006 | 3 | 79 | 33 | 18 | 133 |
| 2007 | 1 | 47 | 24 | 27 | 99 |
| 2008 | 0 | 50 | 5 | 29 | 84 |
| 1–6/2009 | 2 | 21 | 7 | 13 | 43 |
| High-dose Regimen (N patients) | |||||
| TBI-based | 152 | 114 | -- | -- | 266 |
| Non TBI-based | 299 | 117 | -- | -- | 416 |
| Low-dose Regimen (N patients) | |||||
| Flu-2 (3) Gy TBI | -- | -- | 232 | 100 | 332 |
| 2 Gy TBI | -- | -- | 48 | 27 | 75 |
Flu – fludarabine; HD – high dose; LD- low dose; PBSC – G-mobilized peripheral blood stem cells; TBI-total body irradiation.